Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adamas Pharmaceuticals IncADMS · Entity 133085 | Chief Operating Officer | June 21, 2018 | June 22, 2018 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director · Chief Executive Officer | June 30, 2021 | July 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adamas Pharmaceuticals Inc
Report date June 21, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,856 |
Reported balance
After 2018-06-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-21 · Sale · Disposed 2,501 · Balance 48,856 F1: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2: The shares were sold at prices ranging from $25.42 to $25.53. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: Includes 696 shares purchased on 5/31/18 through the issuer's employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
F2: The shares were sold at prices ranging from $25.42 to $25.53. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Includes 696 shares purchased on 5/31/18 through the issuer's employee stock purchase plan.
SPRUCE BIOSCIENCES, INC.
Report date June 30, 2021 · Filed July 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,230 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Other · Acquired 2,230 · Balance 2,230 F1: Shares acquired by Mr. King pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired by Mr. King pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 6, 2021 16:12 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | OtherCommon Stock | 2,230 | $9.53 | $21,248.56 |
DisclosureSEC source: 0001209191-21-045418 · doc4.xml · nonDerivative · entry 1 KING RICHARD · CIK 0001013702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,230 F1 · shares: Shares acquired by Mr. King pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:49 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001209191-21-006375 · doc4.xml · derivative · entry 1 KING RICHARD · CIK 0001013702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares vest over a four-year period commencing January 28, 2021, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:47 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 2,501 | $25.48 | $63,725.48 |
DisclosureSEC source: 0001209191-18-039249 · doc4.xml · nonDerivative · entry 1 KING RICHARD · CIK 0001013702 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,856 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $25.42 to $25.53. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 696 shares purchased on 5/31/18 through the issuer's employee stock purchase plan. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:46 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 66,000 | $0.00 Strike: $25.66 | $0.00 |
DisclosureSEC source: 0001209191-18-018671 · doc4.xml · derivative · entry 2 KING RICHARD · CIK 0001013702 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2028-03-05 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:46 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-018671 · doc4.xml · nonDerivative · entry 1 KING RICHARD · CIK 0001013702 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,661 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2019, March 20, 2020, March 20, 2021 and March 20, 2022, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 12:14 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 10,000 | $25.07 | $250,700.00 |
DisclosureSEC source: 0001209191-18-014826 · doc4.xml · nonDerivative · entry 1 KING RICHARD · CIK 0001013702 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,661 F1 · price: The shares were purchased at prices ranging from $25.05 to $25.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 1,536 shares purchased on 11/30/17 through the issuer's employee stock purchase plan. Read SEC document |
| May 05, 2017 Filed May 5, 2017 17:31 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $17.40 | $0.00 |
DisclosureSEC source: 0001209191-17-030401 · doc4.xml · derivative · entry 2 KING RICHARD · CIK 0001013702 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2027-05-04 F2 · derivative.exercise_date: The shares subject to the option shall become vested according to the following schedule: 25% of the shares subject to the option shall vest on April 28, 2018, and the remaining shares will vest in equal monthly installments over the next 36 months. Read SEC document |
| May 05, 2017 Filed May 5, 2017 17:31 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-030401 · doc4.xml · nonDerivative · entry 1 KING RICHARD · CIK 0001013702 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 F1 · shares: Represents the grant of restricted stock units that vest 1/4th on each of June 20, 2018, June 20, 2019, June 20, 2020, and June 20, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.